The medication Limbrel is allegedly causing serious life-threatening issues for users. The FDA is investigating this drug, a prescription product to help meet nutritional requirements of patients with osteoarthritis. Among many serious adverse events, two severe injuries are drug-induced liver injury and hypersensitivity pneumonitis.
The FDA received 194 adverse event reports related to the use of Limbrel. Of these, 57 cases have sufficient information that the FDA will use to analyze whether Limbrel was the actual cause of the adverse event. 30 of the 194 cases have sufficient information to apply the Council for International Organizations of Medical Sciences (CIOMS) causality assessment method. This method is used to determine the likelihood that there is an association between Limbrel and the reported adverse event.
GoldenbergLaw has over 30 years of experience handling dangerous drugs and is committed to holding drug manufacturers and suppliers responsible in these circumstances. Contact Senior Partner Stuart Goldenberg for any questions on Limbrel or other dangerous drugs and supplements.